Piper Sandler Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by Piper Sandler from $23.00 to $20.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Piper Sandler’s price objective would indicate a potential upside of 5.54% from the company’s current price.

SRPT has been the topic of a number of other research reports. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Deutsche Bank Aktiengesellschaft upped their price objective on Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Nine investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and seven have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.09.

Sarepta Therapeutics Stock Down 7.7%

Shares of NASDAQ:SRPT opened at $18.95 on Thursday. The firm has a market capitalization of $2.00 billion, a PE ratio of -19.74, a price-to-earnings-growth ratio of 0.22 and a beta of 0.21. The business has a 50 day simple moving average of $17.75 and a two-hundred day simple moving average of $19.29. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $25.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the company earned ($3.42) earnings per share. On average, equities analysts predict that Sarepta Therapeutics will post 3.95 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Mirador Capital Partners LP purchased a new stake in Sarepta Therapeutics in the fourth quarter valued at $3,012,000. Boxer Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 900.0% in the 3rd quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock valued at $4,818,000 after acquiring an additional 225,000 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Sarepta Therapeutics by 143.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after purchasing an additional 62,981 shares during the period. Union Square Park Capital Management LLC acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at approximately $2,023,000. Finally, Quinn Opportunity Partners LLC raised its holdings in shares of Sarepta Therapeutics by 29.9% in the 3rd quarter. Quinn Opportunity Partners LLC now owns 376,244 shares of the biotechnology company’s stock valued at $7,250,000 after buying an additional 86,522 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Wolfe Research upgraded Sarepta Therapeutics to outperform and set a $27 price target, signaling meaningful upside potential. Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Outperform at Wolfe Research
• Neutral Sentiment: Piper Sandler trimmed its price target on Sarepta to $20 from $23 but kept a neutral rating, suggesting limited near-term conviction rather than a clear bearish call. Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $20.00 at Piper Sandler
• Negative Sentiment: Broad biotech-sector weakness is weighing on Sarepta and peers like Moderna and ImmunityBio, with investors pulling back after a strong 2026 rally in the group. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
• Negative Sentiment: Zacks Research downgraded Sarepta to strong sell, adding to the negative sentiment around the stock. Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.